109

future R&D funding programmes already implemented or committed, especially so through the Horizon 2020 programme. Most importantly, the wider impacts of the sector`s development can result in numerous inventions benefiting the wider society – including those in the areas of health, food, pharmaceuticals and energy. 6.2 Monitoring and evaluation In order to assess and monitor whether the selected policies have delivered the expected results a list of specific indicators need to be compiled that correlate with the individual initiatives. The assessment of these indicators can be both qualitative and quantitative. As the selected policy options (Options 2 and 3) contain initiatives that could be assessed in both qualitative and quantitative terms it is suggested that both types of assessments are carried out. Table 6.1 gives an overview of the possible indicators to follow for the future evaluation of initiatives under Options 2 and 3. Table 6.1 Monitoring indicators Initiative Option 2 2A. Support the development of the Marine Biotechnology ERA-NET Number of new research and product development collaborations Number of new enterprises (special focus on SMEs) that have previously have not been involved in consortiums under ERA-NET Number of new products marketable prototypes entering the market as a result of collaboration within ERA-NET projects Utilisation (% share) of EU biotechnology infrastructure (including biobanks and research vessels) in ERANET projects 2H. Establish a Blue Growth bridging fund Number and value of applications for financial support from the bridging fund Number and value of financial loans approved from the bridging funds Commercial value of products developed using the bridging loan Share of venture capital investment in the Blue Biotechnology sector Option 3 3G- Promote Blue Biotech funding through existing financing instruments Number of companies active in the sector Number of Blue Biotechnology projects/consortiums seeking financial support Number of new technologies, processes and products in Blue Biotechnology realised through the project supported Spin-off projects and marketable products realised as a follow-up of the support Indicator 84 Study in support of Impact Assessment work on Blue Biotechnology

110 Publizr Home